Please use this identifier to cite or link to this item:
|Title:||Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug–drug interactions of drugs of abuse|
Maurer, Hans H.
Meyer, Markus R.
|Title:||Archives of Toxicology|
|Year of Publication:||2018|
|Free key words:||Drugs of abuse|
|DDC notations:||500 Science |
570 Life sciences, biology
|Publikation type:||Journal Article|
|Abstract:||Transporter-mediated drug–drug interactions (DDI) may induce adverse clinical events. As drugs of abuse (DOA) are marketed without preclinical safety studies, only very limited information about interplay with membrane transporters are available. Therefore, 13 DOA of various classes were tested for their in vitro affinity to the human breast cancer resistance protein (hBCRP), an important efflux transporter. As adenosine 5′-triphosphate (ATP) hydrolysis is crucial for hBCRP activity, adenosine 5′-diphosphate (ADP) formation was measured and used as in vitro marker for hBCRP ATPase activity. ADP quantification was performed by hydrophilic interaction liquid chromatography coupled to high-resolution tandem mass spectrometry and its amount in test compound incubations was compared to that in reference incubations using the hBCRP substrate sulfasalazine or the hBCRP inhibitor orthovanadate. If DOA caused stimulation or inhibition, further investigations such as Michaelis–Menten kinetic modeling or IC50 value determination were conducted. Among the tested DOA, seven compounds showed statistically significant hBCRP ATPase stimulation. The entactogen 3,4-BDB and the plant alkaloid mitragynine were identified as strongest stimulators. Their affinity to the hBCRP ATPase was lower than that of sulfasalazine but comparable to that of rosuvastatin, another hBCRP model substrate. Five DOA showed statistically significant hBCRP ATPase inhibition. Determination of IC50 values identified the synthetic cannabinoid receptor agonists JWH-200 and WIN 55,212-2 as the strongest inhibitors comparable to orthovanadate. The present study clearly demonstrated that tested DOA show in part high affinities to the hBCRP within the range of model substrates or inhibitors. Thus, there is a risk of hBCRP-mediated DDI, which needs to be considered in clinical settings.|
|DOI of the first publication:||10.1007/s00204-018-2276-y|
|Link to this record:||urn:nbn:de:bsz:291--ds-309074|
|Date of registration:||20-May-2020|
|Faculty:||M - Medizinische Fakultät|
|Department:||M - Experimentelle und Klinische Pharmakologie und Toxikologie|
|Professorship:||M - Prof. Dr. Markus Meyer|
|Collections:||SciDok - Der Wissenschaftsserver der Universität des Saarlandes|
Files for this record:
|Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse_mit_Vorblatt.pdf||Accepted Manuscript||1,04 MB||Adobe PDF||View/Open|
Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.